Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: A systematic review

BMJ Open

Volumn 2, Issue 3, 2012, Pages

  Farrimond, Lucy E ^a   Roberts, Emmert ^b   McShane, Rupert ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b BRISTOL ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABIXA; CHOLINESTERASE INHIBITOR; DIHYDROERGOTOXINE MESILATE; MEMANTINE; MEMOX; PLACEBO; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BEHAVIOR; CLINICAL STUDY; COGNITION; DISEASE REGISTRY; DRUG EFFICACY; DRUG LEGISLATION; EUROPE; HUMAN; MENTAL PATIENT; META ANALYSIS; MOOD; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

EID: 84863669083     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-000917     Document Type: Review

References (27)

1. EMEA Committee for Medicinal Products for Human Use. October 2005 Plenary Meeting Monthly Report. European Medicines Agency Website. http://www.emea. europa.eu/pdfs/human/press/pr/ 36234805-n.pdf (accessed 17 Nov 2005).
2. National Institute for Clinical Excellence (NICE). Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease. NICE Technology Appraisal Guidance 217 (Review of NICE Technology Appraisal Guidance 111). National Institute for Clinical Excellence, 2011. http://publications.nice.org.uk/ donepezil-galantamine-rivastigmine-and- memantine-for-the-treatmentof- alzheimers-disease-ta217/guidance (accessed 23 Mar 2012).
3. Institute for Quality and Efficiency in Healthcare (IQWiG). Memantine in Alzheimer's Disease. Executive Summary of Final Report A05-19C. Institute for Quality and Efficiency in Healthcare (IQWiG), 2009. https://www.iqwig.de/ download/A05-19C-Executive- Summary-Memantine-in-Alzheimers-disease.pdf (Translation of the executive summary of the final report "Memantin bei Alzheimer Demenz") (accessed 23 Mar 2012).
4. Institute for Quality and Efficiency in Health Care (IQWiG). Federal Joint Committee. Responder Analyses on Memantine in Alzheimer's Disease: Executive Summary of Rapid Report A10-06. Institute for Quality and Efficiency in Healthcare (IQWiG), 2011. https://www. iqwig.de/download/A10-06-Executive- summary-Responder-analyses-on-memantine-in-Alzheimers-disease.pdf (accessed 23 Mar 2012).
5. Institute for Quality and Efficiency in Healthcare (IQWiG). Press Release: Memantine in Alzheimer's Disease: Reliable Analyses are Required. Institute for Quality and Efficiency in Healthcare (IQWiG), 2010. https://www.iqwig.de/memantine-in-alzheimer-s-diseasereliable. 1079.en.html (accessed 23 Mar 2012).
6. Patel L, Grossberg GT. Combination therapy for Alzheimer's disease. Drugs Aging 2011;28:539-46.
7. Schneider LS, Dagerman KS, Higgins JPT, et al. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol 2011;68:991-8.
8. Bond M, Rogers G, Peters J, et al. The Effectiveness and Cost- Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of TA111): A Systematic Review and Economic Model. NIHR HTA Programme Project Number 09/87/01. National Institute for Clinical Excellence, 2010. http://guidance.nice.org.uk/TA/WaveR111/1/ AssessmentReport (accessed 23 Mar 2012).
9. Tariot P, Farlow M, Grossberg T, et al. For the memantine study group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donopezil. A randomized controlled trial. JAMA 2004;291:317-24. (Pubitemid 38101604)
10. Porsteinsson AP, Grossberg GT, Mintzer J, et al. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 2008;5:83-9. (Pubitemid 351536358)
11. Winblad B, Jones RW, Wirth Y, et al. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn 2007;24:20-7. (Pubitemid 46985287)
12. The Cochrane Dementia and Cognitive Improvement Group (CDCIG). ALOIS: A Comprehensive Register of Dementia Studies. ALOIS. http://www.medicine.ox.ac.uk/ alois/ (accessed 23 Mar 2012).
13. McShane R, Marcus S; Cochrane Dementia and Cognitive Improvement Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs). Cochrane Dementia and Cognitive Improvement Group (CDCIG), 2010:4. http://onlinelibrary. wiley.com/ o/cochrane/clabout/articles/DEMENTIA/frame.html (accessed 23 Mar 2012).
14. Review Manager (RevMan) [Computer Program]. Version 5.0. Copenhagen, Denmark: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
15. Forest Laboratories. Study No MEM-MD-50: A Randomized, Double- Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Patients with Moderate-to-Severe Dementia of the Alzhiemer's Type. Forest Laboratories Clinical Trials Registry, 2008. http://www.forestclinicaltrials. com/CTR/CTRController/CTRViewPdf? -file-id=scsr/SCSR-MEM-MD-50-final.pdf (accessed 23 Mar 2012).
16. Lundbeck Trials. Clinical Trial Report Summary: Study 10112. A 1- Year Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Memantine on the Rate of Brain Atrophy in Patients With Alzheimer's Disease. H. Lundbeck A/S, 2012. http://www.lundbecktrials.com/Data/PDFs/10112-Final%20CTRS- 28May2010.pdf (accessed 23 Mar 2012).
17. Study ID: NCT00866060. Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD). Clinicaltrials.gov. http:// clinicaltrials.gov/ct2/show/NCT00866060?term=DOMINO&rank=3 (accessed 14 Aug 2011).
18. Forest Laboratories. Forest and Merz Announce FDA Approval of NAMENDA XR for the Treatment of Moderate to Severe Dementia of the Alzheimer's Type. Forest Laboratories, Inc, 2010. http://news.frx. com/press-release/product-news/ forest-and-merz-announce-fdaapproval- namenda-xr-treatment-moderate-sever (accessed 23 Mar 2012).
19. Wilkinson D, Fox N, Barkhof F, et al. Evaluating the effect of memantine on the rate of brain atrophy in patients with Alzheimer's disease: a multicentre imaging study using a patient enrichment strategy. Poster Presented at: 14th International Congress of the International Psychogeriatric Association; 1-5 September 2009, Montréal, Canada. H. Lundbeck A/S, 2009.
20. Peninsula Technology Assessment Group (PenTAG), University of Exeter AChEIs and Memantine for Alzheimer's Disease: PenTAG Responses to Consultee Comments. National Institute for Clinical Excellence. http://www.nice.org.uk/ nicemedia/live/12248/51068/ 51068.pdf (accessed 17 Aug 2010).
21. Periclou A, Hu Y. Extended-release memantine capsule (28 mg, once daily): a multiple dose, open-label study evaluating steady-state pharmacokinetics in healthy volunteers [abstract from poster presentation]. Presented at the 11th International Conference on Alzheimer's Disease; 26-31 July 2008. Chicago, IL, USA. Forest Laboratories Inc. 2008.
22. Hardingham GE, Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci 2010;11:682-96.
23. Lovera JF, Frohman E, Brown TR, et al. Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial. Mult Scler 2010;16:715-23.
24. Villoslada P, Arrondo G, Sepulcre J, et al. Memantine induces reversible neurologic impairment in patients with MS. Neurology 2009;72:1630-3.
25. Reisberg B, Doody R, Stoffler A, et al. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 2006;63:49-54. (Pubitemid 43063861)
26. Forest Laboratories Inc. An Open-Label Evaluation of the Safety of Memantine in Patients with Moderate-to-Severe Dementia of the Alzheimer's Type. Forest Laboratories Clinical Trials Registry, 2005. http://www. forestclinicaltrials.com/CTR/CTRController/ CTRViewPdf?-file-id=scsr/SCSR-MEM- MD-51-final.pdf (accessed 23 Mar 2012).
27. Forest Laboratories Inc. An Open-Label Extension Study Evaluating the Safety and Tolerability of Memantine in Patients with Moderateto- Severe Dementia of the Alzheimer's Type. Forest Laboratories Clinical Trials Registry, 2009. http://www.forestclinicaltrials.com/CTR/ CTRController/CTRViewPdf?-file- id=scsr/SCSR-MEM-MD-54-final.pdf (accessed 23 Mar 2012).